In AF and stable CAD, rivaroxaban reduced cardiovascular events and mortality more than rivaroxaban plus an antiplatelet
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Internal Medicine"
DOI: 10.7326/acpj202001210-006
Abstract: Source Citation Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381:1103-13. 31475793 read more here.
Keywords: rivaroxaban reduced; stable cad; cardiovascular events; reduced cardiovascular ... See more keywords